CN107748253A - A kind of ELISA detection method of Fc γ RI acceptors - Google Patents

A kind of ELISA detection method of Fc γ RI acceptors Download PDF

Info

Publication number
CN107748253A
CN107748253A CN201710616069.0A CN201710616069A CN107748253A CN 107748253 A CN107748253 A CN 107748253A CN 201710616069 A CN201710616069 A CN 201710616069A CN 107748253 A CN107748253 A CN 107748253A
Authority
CN
China
Prior art keywords
detection method
vegf
elisa
acceptors
vegf mab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710616069.0A
Other languages
Chinese (zh)
Inventor
朱文娟
艾洪新
龙水清
刘西燕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tot Biopharm Co Ltd
Original Assignee
Tot Biopharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tot Biopharm Co Ltd filed Critical Tot Biopharm Co Ltd
Priority to CN201710616069.0A priority Critical patent/CN107748253A/en
Publication of CN107748253A publication Critical patent/CN107748253A/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A kind of ELISA detection method of claimed Fc γ RI CD64 acceptors, the step of it is included in the coating step that Fc γ RI CD64 are coated with ELISA Plate, closing, sample preparation, secondary antibody are incubated, substrate colour developing, and the sample preparation step is：After anti-VEGF mAb mixes with antigen, a hour formation immune complex is stood；Immune complex progress gradient dilution is added to be coated with Fc γ RI CD64 ELISA Plate and is incubated.Compared with the ELISA method of routine, this method provides a kind of new analysis method for the assessment of anti-VEGF mAb and Fc γ RI CD64 binding activity.

Description

A kind of ELISA detection method of Fc γ RI acceptors
Technical field
The invention belongs to biological technical field, and in particular to a kind of ELISA detection method of Fc γ RI (CD64) acceptor.
Background technology
VEGF (vascular endothelial growth factor, VEGF), is blood vessel endothelium The HBGF of cell-specific, can in vivo induction of vascular it is newborn.VEGF also may be used by different tumor cell secretions Developmental normal cell and tissue in express, in vivo adjust blood vessel permeability, be vascularization during it is a variety of Cell provides a network of fibers；The degraded of matrix and propagation, migration, motion and the blood vessel of endothelial cell can be promoted in vitro The formation of chamber spline structure, and the endothelial progenitor cells of derived from bone marrow can be mobilized.VEGF be the effect of induced tumor vascularization it is most strong, Specific highest angiogenesis factor.So in theory, employ different approach to intervene or suppress vascular endothelial growth The factor can suppress the growth of tumour.
Therapeutic monoclonal antibodies are widely used in the treatment such as tumour, autoimmune disease, infectious diseases.Monoclonal antibody removes Have the characteristics that specific high, adverse reaction is small and mechanism of action it is clear and definite outside, long half time is also its unique advantage.Current Therapeutic monoclonal antibody is mostly immunoglobulin G (immunoglobulin G, IgG), it has also become one kind is tackled cancer and itself exempted from The critical treatment means of epidemic disease.The effect of monoclonal antibody, depends not only upon its antibody binding domain (Fab), while its crystallizable region (Fc) also play an important role.Fab can specifically identify tumor associated antigen (TAA), so as to regulate and control the related downstreams of TAA Signal path.Fc can play series of effects function such as ADCC, ADCP and CDC, further the effect of lifting monoclonal antibody, while Fc FcRn can also be combined so as to extend the half-life period of monoclonal antibody medicine.
With requiring to improve constantly to monoclonal antibody drug effect, it is current monoclonal antibody to select suitable IgG hypotypes and the transformation of Fc regions One focus of research and development.Internal many cell surfaces have inhomogeneity Ig Fc acceptor, by Fc acceptors and Ig Fc combination, Participate in the physiological function or pathology damage process of Ig mediations.Identify that the Fc acceptors for unambiguously belonging to T cell differentiation antigen there are Fc γ RI at present (CD64)、FcγRII(CD32a,b,c)、FcγRIII(CD16a,b,c)。
Fc γ RI (CD64) are the membrane glycoproteins of wearing that size is 70kDa, belong to Ig superfamily members, and after birth outskirt has 3 C2 Structure, Genetic food is in 1q23~24.Identification CD64 representative McAb has McAb22, McAb32.2,197 and 10.1 Deng.Fc γ RI (CD64) are high affinity receptors, and Kd values are 10-8~10-9M, mainly with monomer IgG1, IgG3 of people and small Mouse IgG2a and IgG3 are combined.The affinity combined with human IgG 4 clearly reduces, with IgG2 then without binding ability.FcγRI (CD64) monocyte, macrophage, neutrophil leucocyte etc. are distributed mainly on, but expression is different.FcγRI (CD64) number of sites：15000~40000/ each monocytes,>50000/ macrophage,<1000/ fresh neutrophil leucocyte. IFN-＆gamma can stimulate monocyte, macrophage and horizontal 5~10 times of the increases of neutrophil leucocyte expression Fc γ RI (CD64), G-CSF also has this facilitation.
In recent years, biomembrane interference technique (biolayerinterferomeory, BLI), biacore technologies etc. are used for The measure of Fc γ RI (CD64) binding activity, although simple and efficient, expensive large scale equipment is needed, is unfavorable for common reality Test the tracking and monitoring of room, the technical research of small-sized biological company and product quality.And enzyme-linked immunosorbent assay (ELISA) side Method, because its is simple to operate, quick, sensitiveness is high, high specificity, equipment requirement are simple, therefore in laboratory extensive use.
The content of the invention
The technical problems to be solved by the invention are innovative utilization sandwich ELISA method detection anti-vegf lists of the invention The anti-binding ability with Fc γ RI (CD64) acceptor, make antibody samples in vitro with the binding activity of Fc γ RI (CD64) acceptor Detection can be simpler easy.Using this patent detection method can in vitro it is quick, directly detect anti-VEGF mAb and Fc γ RI (CD64) receptor-binding activity, and cost is relatively low, convenient experimental operation, it is reproducible, as a result judge objective, sensitivity It is high.Conformance Assessment and clinical drug effect and pharmacokinetic for anti-VEGF mAb also provide reference information.
In order to solve the above-mentioned technical problem, technical scheme provided by the invention is that one kind ELISA method detects anti-vegf The binding activity of monoclonal antibody and Fc γ RI-CD64 acceptors, i.e., a kind of ELISA detection method of Fc γ RI-CD64 acceptors, it is included in On ELISA Plate the step of coating Fc γ RI-CD64 coating step, closing, sample preparation, secondary antibody incubation, substrate colour developing, and institute Stating sample preparation step is：After anti-VEGF mAb mixes with antigen, a hour formation immune complex is stood；.With routine ELISA method is compared, and this method provides a kind of new point for the assessment of anti-VEGF mAb and Fc γ RI (CD64) binding activity Analysis method.
In currently preferred technical scheme, the mol ratio of anti-VEGF mAb and antigen is 0.1~10:Between 1；It is preferred that Ground, the mol ratio of the anti-VEGF mAb and antigen is 0.5~5:Between 1, it is highly preferred that mole of anti-VEGF mAb and antigen Than 1~3:Between 1.
In currently preferred technical scheme, gradient dilution is carried out to immune complex, addition has been coated with Fc γ RI-CD64 ELISA Plate on be incubated.
The anti-VEGF mAb includes but is not limited to Avastin BEVACIZUMAB (Avastin).
In currently preferred technical scheme, the molecular formula and molecular weight of the anti-VEGF mAb are： C6638H10160N1720O2108S44149kDa, its light-chain amino acid sequence are as follows：
DIQMTQSPSS LSASVGDRVT ITCSASQDIS NYLNWYQQKP GKAPKVLIYF TSSLHSGVPSRFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSTVPWTFGQGTKVEIKRTV AAPSVFIFPPSDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQG LSSPVTKSFN RGEC；
The amino acid sequence of heavy chain is：
EVQLVESGGG LVQPGGSLRL SCAASGYTFT NYGMNWVRQA PGKGLEWVGW INTYTGEPTY AADFKRRFTF SLDTSKSTAY LQMNSLRAEDTAVYYCAKYP HYYGSSHWYF DVWGQGTLVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC LVKDYFPEPV TVSWNSGALT SGVHTFPAVLQSSGLYSLSS VVTVPSSSLG TQTYICNVNH KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP PKPKDTLMIS RTPEVTCVVV DVSHEDPEVKFNWYVDGVEV HNAKTKPREE QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR EPQVYTLPPS REEMTKNQVSLTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK。
A kind of recombinant humanized Anti-X activity of the present invention is a kind of therapeutic monoclonal antibodies product, and it can VEGF (vascular endothelial growth factor, VEGF) is specifically bound, and is blocked VEGF biological activity, to suppress angiogenesis, so as to reach antitumor action.Chinese storehouse is passed through using recombinant DNA technology The recombinant humanized monoclonal IgG1 antibody of mouse ovary (Chinese hamster ovary, CHO) cell expression system production, The mouse source monoclonal antibody complementary determining region sequence with reference to people VEGF comprising 93% Human monoclonal antibody sequence and 7%, heavy chain is by 453 Amino acid is formed, and light chain is made up of 214 amino acid, and molecular weight is about 149kDa.
Our company anti-VEGF antibody Fc γ RI (CD64) binding activity detection method is to be based on ELISA method, and utilization is parallel Curve (four parameter curves) model determination relative activity.
Brief description of the drawings
Fig. 1 is Fc γ RI (CD64) acceptors and anti-VEGF mAb binding activity detection method detection principle diagram.
Fig. 2 is Fc γ RI (CD64) and anti-VEGF mAb binding curve figure.
Fig. 3 A are the light-chain amino acid sequence figure of anti-VEGF mAb；Fig. 3 B are the heavy chain amino acid sequence of anti-VEGF mAb Figure.
Embodiment
Such scheme is described further below in conjunction with specific embodiment.It should be understood that these embodiments are to be used to illustrate The present invention and be not limited to limit the scope of the present invention.The implementation condition used in embodiment can be done according to the condition of specific producer Further adjustment, unreceipted implementation condition is usually the condition in normal experiment.
Introduce and summarize
The present invention by way of example rather than provides the mode of limitation to illustrate.It should be noted that in present disclosure Described " one " or " one kind " embodiment is not necessarily referring to same embodiment, and refers at least a kind of.
Various aspects of the invention are described below.However, as will be readily apparent to one of skill in the art, can Implement the present invention according to the only some or all of aspects of the present invention.For purposes of illustration, provide herein specific numbering, material and Configuration, enables one to thoroughly understand the present invention.However, be evident that for those of skill in the art, The present invention can be implemented without concrete details.In other examples, not make the present invention is obscure many institutes have been omitted or simplified Known feature.
Various operations are described successively as multiple discrete steps, and with most helpful in the side for understanding the present invention Formula illustrates；However, in-order description should not be construed as to imply that these operations are necessarily dependent on order.
Reactant according to type species is illustrated to various embodiments.To show for those of skill in the art and It is clear to, any number of different types of reactant can be used to implement for the present invention, and be more than those for the purpose of illustration And the reactant provided herein.In addition, also it is evident that, the invention is not limited in any specific mixing is shown Example.
Experiment material and equipment
Basic model eddy mixer, ELIASA (producer：Molecular Devices, model：Spectra Max M2e)、 ELISA Plate (is purchased from：Corning), microwell plate constant temperature oscillator, board-washing machine (are purchased from：Thermo)
Experiment reagent：
Phosphate buffer (PBS solution), sample diluting liquid/washing lotion, confining liquid, nitrite ion TMB, terminate liquid (1M sulphur Acid), antigen rhVEGF165, Fc γ RIIA (H131), Fc γ RIIA (R131), Fc γ RIIB
Test sample：All test samples provide by TOT Biopharm Co., Ltd..
Embodiment：By taking single sample as an example, illustrative step is as follows：
Standard items dilute with sample：
Avastin is first diluted to 1~3 μ g/mL, then 8~11 concentration of gradient dilution with sample diluting liquid.
Experimental procedure：
(1) each hole of ELISA Plate is added with the μ g/ml antigen coats liquid of 100 μ l 1~5；After being sealed with sealed membrane, 2-8 DEG C is placed in Under the conditions of be incubated 16-20 hours.
(2) take out after ELISA Plate discards coating buffer, machine-washed plate 2 times with 300 μ l washing lotions board-washings, plate is patted dry on filter paper.
(3) 100 μ l confining liquids are added in each hole, after being sealed with sealed membrane, 200rpm is in micropore at ambient temperature Shaking is incubated 1~2h in plate oscillator.
(4) microwell plate is removed from micropore plate oscillator, topples over content, patted dry.Add 300 μ l washing lotion board-washing machines clear per hole Wash, pat dry, be repeated 4 times.
(5) for the microwell plate being coated with, respectively in working hole plus gradient dilution the μ l of test sample 100.Use sealed membrane After sealing, 200rpm shakings at ambient temperature are incubated 1~2h.
(6) microwell plate is removed from micropore plate oscillator, topples over content, patted dry.Add 300 μ l washing lotion board-washing machines clear per hole Wash, pat dry, be repeated 6 times.
(7) the ELIAS secondary antibody dilutions of 100 μ l, 5000~10000 times of dilutions are added in every hole, after being sealed with sealed membrane, 200rpm shakings at ambient temperature are incubated 1~2h.
(8) microwell plate is removed from micropore plate oscillator, topples over content, patted dry.Add 300 μ l washing lotion board-washing machines clear per hole Wash, pat dry, be repeated 6 times.
(9) 100 μ l TMB nitrite ions, sealing are added in each working hole respectively, room temperature lucifuge is incubated 20~30 minutes, work Make hole and blueness occur.
(10) add 100 μ l terminate liquid respectively per hole, rap microwell plate mixing, enzyme reaction terminates, and originally shows the hole of blueness Will yellowing.
(11) in terminating reaction half an hour, light absorption value is surveyed in 450nm wavelength, produces the dosage of standard liquid and sample solution Effect curve.
(12) carried out curve fitting calculating using SOFTMAX softwares, obtain curvilinear equation.Specific embodiment described above is only It is the preferred embodiment of the present invention, it is noted that for those skilled in the art, do not departing from this hair On the premise of bright principle, some improvement or replacement can also be made, these improve or replaced the protection that should also be as being considered as the present invention Scope.

Claims (5)

1. a kind of ELISA detection method of Fc γ RI acceptors, it is characterised in that it, which is included on ELISA Plate, is coated with Fc γ RI- The step of CD64 coating step, closing, sample preparation, secondary antibody incubation, substrate develop the color, and the sample preparation step is：It is anti- After VEGF monoclonal antibody mixes with antigen, a hour formation immune complex is stood.
2. detection method according to claim 1, it is characterised in that the mol ratio of the anti-VEGF mAb and antigen exists 0.1~10:Between 1.
3. detection method according to claim 1, it is characterised in that the mol ratio of the anti-VEGF mAb and antigen exists 0.5~5:Between 1.
4. detection method according to claim 1, it is characterised in that gradient dilution is carried out to the immune complex, added Enter to be coated with and be incubated on Fc γ RI-CD64 ELISA Plate.
5. detection method according to claim 1, it is characterised in that the anti-VEGF mAb is Avastin.
CN201710616069.0A 2017-07-26 2017-07-26 A kind of ELISA detection method of Fc γ RI acceptors Pending CN107748253A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710616069.0A CN107748253A (en) 2017-07-26 2017-07-26 A kind of ELISA detection method of Fc γ RI acceptors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710616069.0A CN107748253A (en) 2017-07-26 2017-07-26 A kind of ELISA detection method of Fc γ RI acceptors

Publications (1)

Publication Number Publication Date
CN107748253A true CN107748253A (en) 2018-03-02

Family

ID=61255378

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710616069.0A Pending CN107748253A (en) 2017-07-26 2017-07-26 A kind of ELISA detection method of Fc γ RI acceptors

Country Status (1)

Country Link
CN (1) CN107748253A (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1763097A (en) * 1999-01-15 2006-04-26 杰南技术公司 Polypeptide variants with altered effector function
CN101268372A (en) * 2005-07-21 2008-09-17 根马布股份公司 Potency assays for antibody drug substance binding to FC receptor
US20130315907A1 (en) * 2012-05-22 2013-11-28 Regeneron Pharmaceuticals, Inc. Vegf-a121 assay
CN103460048A (en) * 2011-02-22 2013-12-18 伯恩哈德－诺策热带医学研究所 Detection of antibodies using an improved immune complex (IC) ELISA
WO2017048699A2 (en) * 2015-09-14 2017-03-23 Galaxy Biotech Llc Highly potent monoclonal antibodies to angiogenic factors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1763097A (en) * 1999-01-15 2006-04-26 杰南技术公司 Polypeptide variants with altered effector function
CN101268372A (en) * 2005-07-21 2008-09-17 根马布股份公司 Potency assays for antibody drug substance binding to FC receptor
CN103460048A (en) * 2011-02-22 2013-12-18 伯恩哈德－诺策热带医学研究所 Detection of antibodies using an improved immune complex (IC) ELISA
US20130315907A1 (en) * 2012-05-22 2013-11-28 Regeneron Pharmaceuticals, Inc. Vegf-a121 assay
WO2017048699A2 (en) * 2015-09-14 2017-03-23 Galaxy Biotech Llc Highly potent monoclonal antibodies to angiogenic factors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROBERT L.SHIELDS, ET AL.: "High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR.", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 *

Similar Documents

Publication Publication Date Title
KR101681550B1 (en) Composition comprising two or more influenza A viruses neutralizing binding molecules
CN102007147B (en) Anti-CD27 antibody
KR102543878B1 (en) Anti-VEF-A and Anti-ANG2 Antibodies and Uses Thereof
EA023406B1 (en) Anti-hepcidin antibodies and uses thereof
CN102918059A (en) Anti-CD27 antibody
CN102712923B (en) Anti-IgA1 antibody
US20220396626A1 (en) Anti-cll1 antibody and use thereof
CN111971308A (en) B7-H4 antibodies and methods of use thereof
CN115916817A (en) Anti-idiotypic antibodies directed against BCMA-targeting binding domains and related compositions and methods
CN110655579B (en) Novel anti-CT L A-4 monoclonal antibody and application thereof
CN101935349B (en) Humanized monoclonal antibody against human vascular endothelial growth factor and preparation and application thereof
CN109748965A (en) Full source of people PD-L1 monoclonal antibody and its preparation method and application
CN110418842A (en) PD-L1 detects anti-PD-L1 antibody
CN107748253A (en) A kind of ELISA detection method of Fc γ RI acceptors
CN105504062A (en) Detecting antibody for CD6-resistant monoclonal antibody T1h and application
Suzuki et al. Development of anti-drug monoclonal antibody panels against adalimumab and infliximab
CN112010972B (en) Antibody combined with human LAG-3 protein and encoding gene and application thereof
AU2020289850B2 (en) Anti-vegf-a antibodies and uses thereof
CN111205371B (en) Antibody for resisting lymphocyte activating gene 3 and application
CN102863530A (en) Fat cell differentiation metabolite IGF-1 antibody, chip including same and application of fat cell differentiation metabolite IGF-1 antibody
CN110133278A (en) It is a kind of for detecting the external kit of people&#39;s vegf protein expression
CN110031616A (en) A kind of detection kit of auxiliary diagnosis disease
CN107748258A (en) A kind of ELISA detection method of Fc γ RII acceptors
CN109696461A (en) A kind of clearance detection method of therapeutic antibodies
CN107748262A (en) A kind of ELISA detection method of Fc γ RIIIA acceptors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180302